HCV Treatment
EASL 2017: Triple Combination Cures Most Hepatitis C Patients with Prior DAA Failure
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 01 May 2017 00:00
- Written by Liz Highleyman
Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a 3-drug combination being developed by Merck, researchers reported at the EASL International Liver Congress last month in Amsterdam.
EASL 2017: Generic Hepatitis C Drugs Continue to Produce High Cure Rates
- Details
- Category: Approved HCV Drugs
- Published on Monday, 01 May 2017 00:00
- Written by Keith Alcorn
Treatment with generic versions of direct-acting antiviral drugs (DAAs) for hepatitis C continues to produce similar cure rates to those reported in clinical trials of brand-name drugs, James Freeman reported last month at the EASL International Liver Congress in Amsterdam.
EASL 2017: Children with Hepatitis C Respond Well to Sofosbuvir/Ledipasvir
- Details
- Category: HCV Treatment
- Published on Friday, 21 April 2017 00:00
- Written by Liz Highleyman
Almost all children age 6 to 11 with hepatitis C who were treated with a half-strength tablet of sofosbuvir/ledipasvir were cured, which is important as some of them had advanced liver damage even at that young age, according to a presentation at the at the EASL International Liver Congress this week in Amsterdam.
EASL 2017: New AbbVie Hepatitis C Combination Cures 99% of People with Cirrhosis
- Details
- Category: Experimental HCV Drugs
- Published on Saturday, 22 April 2017 00:00
- Written by Keith Alcorn
A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99% cure rate after 12 weeks of treatment with minimal side effects, Xavier Forns reported on behalf of the EXPEDITION-1 study investigators at the International Liver Congress this week in Amsterdam.
EASL 2017: AbbVie Combination Cures Most People with Genotype 3 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 21 April 2017 00:00
- Written by Keith Alcorn
AbbVie's pangenotypic direct-acting antiviral combination of 2 drugs cured 95% of people with early-stage genotype 3 hepatitis C virus (HCV) infection, the hardest genotype to treat, according to results of the ENDURANCE-3 trial presented at the EASL International Liver Congress this week in Amsterdam.
More Articles...
- Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections
- EASL 2017: International Liver Congress Starts This Week in Amsterdam
- FDA Approves Harvoni and Sovaldi for Adolescents with Hepatitis C
- CROI 2017: Glecaprevir/ Pibrentasvir for HCV Can Be Safely Administered with Common Antiretrovirals
Web Design and Development by